WO2006102533A3 - Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates - Google Patents
Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates Download PDFInfo
- Publication number
- WO2006102533A3 WO2006102533A3 PCT/US2006/010638 US2006010638W WO2006102533A3 WO 2006102533 A3 WO2006102533 A3 WO 2006102533A3 US 2006010638 W US2006010638 W US 2006010638W WO 2006102533 A3 WO2006102533 A3 WO 2006102533A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleoside
- lipid
- methods
- pharmaceutically active
- based formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Novel formulations of nucleoside-lipid conjugates, the methods of preparing them and the methods for administering them are provided. More particularly, methods for making liposomal formulations of nucleoside-cardiolipin and analogues thereof are provided. By encapsulating nucleoside prodrugs, drugs are protected from degradation, thereby extending the drugs' plasma half-life and intracellular release. In addition, compositions that demonstrate greater efficacy and higher cytotoxicity are produced. Accordingly, nucleoside-lipid conjugates that demonstrate greater in-vitro and in-vivo activity are produced.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66460105P | 2005-03-23 | 2005-03-23 | |
US60/664,601 | 2005-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006102533A2 WO2006102533A2 (en) | 2006-09-28 |
WO2006102533A3 true WO2006102533A3 (en) | 2007-12-13 |
Family
ID=37024639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/010638 WO2006102533A2 (en) | 2005-03-23 | 2006-03-23 | Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006102533A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20053519L (en) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Use of compounds comprising fatty acids |
WO2011084610A1 (en) * | 2009-12-16 | 2011-07-14 | Children Medical Center Corporation | Liposomes for preventing the spread of hiv |
CN102144981B (en) * | 2011-04-07 | 2013-02-27 | 海南锦瑞制药股份有限公司 | Gemcitabine hydrochloride lyophilized powder injection and preparation method thereof |
JP2015517087A (en) * | 2012-02-15 | 2015-06-18 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Means and methods for assessing bone disorders |
CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
PT3512863T (en) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
CA3197567A1 (en) | 2017-02-01 | 2018-08-09 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
CN112351799A (en) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | Treatment of HCV infected patients with cirrhosis |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017944A1 (en) * | 2002-08-23 | 2004-03-04 | Neopharm, Inc. | Liposomal gemcitabine compositions for better drug delivery |
-
2006
- 2006-03-23 WO PCT/US2006/010638 patent/WO2006102533A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017944A1 (en) * | 2002-08-23 | 2004-03-04 | Neopharm, Inc. | Liposomal gemcitabine compositions for better drug delivery |
Non-Patent Citations (2)
Title |
---|
ALI ET AL.: "Synthesis and biological evaluation of gemicitabine-lipid conjugate (NEO6002)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, 2005, pages 2571 - 2574, XP004866838 * |
IMMORDINO ET AL.: "Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing liposomes containing lipophilic gemicitabine prodrugs", JOURNAL OF CONTROLLED RELEASE, vol. 100, no. 3, 2004, pages 331 - 346, XP004656456 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006102533A2 (en) | 2006-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006102533A3 (en) | Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
WO2002074247A3 (en) | Pharmaceutical formulations for sustained release | |
WO2007022255A3 (en) | Pharmaceutical formulations for sustained release | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
WO2006124047A3 (en) | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent | |
WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
ZA200709251B (en) | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders | |
HK1096034A1 (en) | A solid dosage form comprising a fibrate | |
CA3094580C (en) | Oral formulations of cytidine analogs and methods of use thereof | |
WO2006084164A8 (en) | Gastric retention and controlled release delivery system | |
WO2006078811A3 (en) | Pharmaceutical formulations and methods of use | |
PL1792927T3 (en) | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient | |
WO2011076749A3 (en) | Solid pharmaceutical dosage form of ticagrelor | |
WO2006099169A3 (en) | Novel liposome compositions | |
AU2003274681A1 (en) | Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release | |
WO2007047948A3 (en) | Intranasal administration of rapid acting insulin | |
WO2007009806A3 (en) | Solid dosage formulations of narcotic drugs having improved buccal adsorption | |
WO2006101882A3 (en) | Medicament delivery formulations, devices and methods | |
AU2003270255A1 (en) | Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve | |
MY143549A (en) | Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases | |
EP2308479A3 (en) | Compounds and compositions for delivering active agents | |
WO2006072070A3 (en) | Pharmaceutical formulations of gallium salts | |
WO2002015959A3 (en) | Compounds and compositions for delivering active agents | |
WO2008003050A3 (en) | Gallium nitrate formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06739437 Country of ref document: EP Kind code of ref document: A2 |